Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography (PET [18F]-MPPF) - PD PAIN - RC31/21-0566

Overview

No summary available.

Registry

who.int

Start Date

January 27, 2023

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Patients with Parkinson's disease defined according to UKPDSBB criteria, Men and women aged between 40 and 80 years, Patients with stable anti\-parkinsonian treatment for at least 4 weeks prior to inclusion, Patients with a MOCA score \> 25, Patients with a HADS\-D score \= 11, Person affiliated or benefiting from a social security scheme., Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

•Patients treated with second line therapy (deep brain stimulation, pump \- duodopa and apokinon), Patients with a history of significant psychiatric pathology according to the investigator, Patients treated with drugs interacting with 5HT1A receptors in the previous 4 weeks (triptan, serotonergic antidepressants), Patients with contraindication to MRI, Patients refusing to be informed of an abnormality discovered during brain imaging, Patients with dyskinesias judged by the investigator to be disabling for imaging, Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision, Pregnant woman, breastfeeding woman